The Cambridge, Massachusetts company is offering 9.72 million shares at $17 to $19 each and plans to list on Nasdaq under the ...

Oct 9 (Reuters) - City Therapeutics on Friday said it is targeting a valuation of up to $956.3 million in its US initial public offering, as biotech companies press ahead with listings despite market ...

VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on ...

Max Darrow reports.

Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.

While biotech increasingly adopts AI for R&D, manufacturing bottlenecks constrain health innovation. AI and robotics have the ...

Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Read more on ...

WASHINGTON — A broad tariff on imported pharmaceuticals took effect at the end of September, and some biopharma companies and ...

Parkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug ...

The latest installment in BioPharma Dive’s data visualization series features a look at the factors pressuring biotech stocks ...

Steven Quay, a biopharmaceutical executive with no background in infectious diseases, is no longer being considered for ...